Tal Zaks is the founder of Exsilio Therapeutics. Exsilio Therapeutics has raised $82M in total funding. Latest round: Series A. Based in Boston, MA.
Tal Zaks, M.D., is the interim CEO and executive chairman of Exsilio Therapeutics (now known as Averna Therapeutics), a genome editing startup that emerged from stealth with $82 million in Series A funding in June 2024. He previously served as Chief Medical Officer at Moderna.
Full founder directory · Investor directory · Company funding database · Fundraising library